


PRODUCT INFORMATION



Tranilast (sodium salt)

Item No. 46383

CAS Registry No.: 104931-56-8
Formal Name: 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propen-1-yl]amino]-benzoic acid, monosodium salt
Synonyms: 3,4-DAA,
N-(3',4'-Dimethoxycinnamoyl) Anthranilic Acid,
SB 252218
MF: $C_{18}H_{16}NO_5 \cdot Na$
FW: 349.3
Purity: $\geq 98\%$
Supplied as: A solid
Storage: $-20^{\circ}C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tranilast (sodium salt) is supplied as a solid. A stock solution may be made by dissolving the tranilast (sodium salt) in the solvent of choice, which should be purged with an inert gas. Tranilast (sodium salt) is soluble (≥ 10 mg/ml) in DMSO.

Description

Tranilast is an antiallergic agent.¹ It inhibits prostaglandin E_2 (PGE_2 ; Item No. 14010) and PGD_2 (Item No. 12010) production induced by A23187 (Item Nos. 11016 | 22030) in isolated rat peritoneal mast cells at 100 μM , as well as LPS-stimulated production of PGE_2 and thromboxane B_2 (TXB_2 ; Item No. 19030) in isolated human monocytes (IC_{50} s = ~ 3 and ~ 35 μM , respectively).^{2,3} Tranilast (500 μM) reduces mast cell degranulation induced by compound 48/80 (Item No. 22173).¹ It inhibits VEGF-stimulated proliferation, migration, and tube formation of bovine retinal endothelial cells (IC_{50} s = 22, 18, and 193 μM , respectively).⁴ Tranilast (200 mg/kg) prevents homologous passive cutaneous anaphylaxis (PCA) in guinea pigs.⁵ Formulations containing tranilast have been used in the treatment of asthma and keloid and hypertrophic scars.

References

1. Baba, A., Tachi, M., Ejima, Y., *et al.* Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing properties. *Cell Physiol. Biochem.* **38**(1), 15-27 (2016).
2. Ikai, K., Ujihara, M., Fujii, K., *et al.* Inhibitory effect of tranilast on prostaglandin D synthetase. *Biochem. Pharmacol.* **38**(16), 2673-2676 (1989).
3. Capper, E.A., Roshak, A.K., Bolognese, B.J., *et al.* Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis. *J. Pharmacol. Exp. Ther.* **295**(3), 1061-1069 (2000).
4. Koyama, S., Takagi, H., Otani, A., *et al.* Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. *Br. J. Pharmacol.* **127**(2), 537-545 (1999).
5. Koda, A., Nagai, H., Watanabe, S., *et al.* Inhibition of hypersensitivity reactions by a new drug, N(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5'). *J. Allergy Clin. Immunol.* **57**(5), 396-407 (1975).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/21/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM